Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Medite Cancer Diagnostics, Inc. (OTC: MDIT).

Full DD Report for MDIT

You must become a subscriber to view this report.


Recent News from (OTC: MDIT)

Daily Insider Ratings Round Up 7/12/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: July, 15 2018 05:47
MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cance...
Source: GlobeNewswire
Date: November, 15 2017 08:00
Medite Cancer Diagnostics reports Q3 results
Medite Cancer Diagnostics ( OTCQB:MDIT ): Q3 EPS of -$0.06 Revenue of $1.69M (-27.8% Y/Y) Press Release More news on: Medite Cancer Diagnostics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: November, 14 2017 17:39
MEDITE Cancer Diagnostics Reports 2017 Third Quarter Financial Results
ORLANDO, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cance...
Source: GlobeNewswire
Date: November, 14 2017 17:24
MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
ORLANDO, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cance...
Source: GlobeNewswire
Date: November, 08 2017 08:31
MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing, Providing Working Capital to Drive Commercial Plan Execution
ORLANDO, Fla., Oct. 03, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cance...
Source: GlobeNewswire
Date: October, 03 2017 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-13N/A0.06N/AN/A1
2018-12-12N/A0.06N/AN/A0
2018-12-11N/A0.06N/AN/A5
2018-12-10N/A0.06N/AN/A0
2018-12-07N/A0.06N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-032,9002,90699.7935Short
2018-11-022,0002,10095.2381Short
2018-10-121002,0064.9850Cover
2018-09-282,7686,37043.4537Short
2018-09-272,5002,500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MDIT.


About Medite Cancer Diagnostics, Inc. (OTC: MDIT)

Logo for Medite Cancer Diagnostics, Inc. (OTC: MDIT)

MEDITE Cancer Diagnostics, Inc. specializes in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions. The Company has a well developed infrastructure with over employees in four countries, a distribution network to about countries worldwide, a well known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

 

Contact Information

 

 

Current Management

  • Stephen Von Rump / CEO
  • Antoinette Torres / Controller
  • John Abeles /
  • W. Austin Lewis IV /
  • Stephen Von Rump /

Current Share Structure

  • Market Cap: $9,416,515 - 03/12/2018
  • Authorized: 100,000,000 - 03/08/2018
  • Issue and Outstanding: 39,565,190 - 03/08/2018

 


Recent Filings from (OTC: MDIT)

Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: May, 17 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Amendment to a previously filed Form 3
Filing Type: 3/AFiling Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (OTC: MDIT)

Daily Technical Chart for (OTC: MDIT)


Stay tuned for daily updates and more on (OTC: MDIT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MDIT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MDIT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MDIT and does not buy, sell, or trade any shares of MDIT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/